SCHEMBL6259622

SCHEMBL6259622

c1ccc(CNc2ccnc(Nc3ccc4[nH]ncc4c3)n2)nc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.67
PTK2B Q14289 1/20 0.67
KDR P35968 10/20 0.60
IGF1R P08069 3/20 0.57
PLK1 P53350 3/20 0.57
MAPKAPK2 P49137 3/20 0.57
ROCK2 O75116 3/20 0.57
SYK P43405 3/20 0.57
CLK2 P49760 3/20 0.57
DYRK1A Q13627 3/20 0.57
CLK4 Q9HAZ1 3/20 0.57
PLK4 O00444 2/20 0.57
CHEK1 O14757 2/20 0.57
MAPK13 O15264 2/20 0.57
PDPK1 O15530 2/20 0.57
DAPK3 O43293 2/20 0.57
DYRK3 O43781 2/20 0.57
JAK2 O60674 2/20 0.57
PRKD3 O94806 2/20 0.57
MAP4K4 O95819 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6239489 0.92 KDR (0.57) PTK2PTK2BKDRIGF1RPLK1
SCHEMBL6236364 0.90 KDR (0.58) PTK2PTK2BKDRIGF1RPLK1
SCHEMBL6260019 0.86 PTK2 (0.52) PTK2PTK2BKDRIGF1RPLK1
SCHEMBL6768877 0.84 PTK2 (0.64) PTK2PTK2BMAPKAPK2ROCK2JAK2
SCHEMBL6260423 0.84 EGFR (0.51) PTK2PTK2BKDRIGF1RSYK
Ammonia Solution, Strong SCHEMBL6833389 0.83 PTK2 (0.58) PTK2PTK2BKDRIGF1RPLK1
SCHEMBL6241400 0.82 PTK2 (0.75) PTK2PTK2BKDRIGF1RCLK2
SCHEMBL6213528 0.82 PTK2 (0.78) PTK2PTK2BKDRIGF1RPLK1
SCHEMBL6209907 0.82 PTK2 (0.75) PTK2PTK2BKDRIGF1RROCK2
SCHEMBL6212988 0.82 PTK2 (0.75) PTK2PTK2BKDRIGF1RSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885KDR 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.